Human rhinoviruses are the major causative agents of the common cold. Because there are greater than 100 viral serotypes, little immunological protection is afforded to humans by prior rhinovirus exposure, which accounts for the high incidence of infection. In most cases, rhinovirus leads to a short self-limiting illness. However, for asthmatics, the elderly and immunocompromised patients, rhinovirus infection can lead to life-threatening complications. This has spurred a consistent effort over recent decades to identify effective treatments and preventions for rhinovirus infection. While some work has focused on alleviating the symptoms induced as a result of inflammatory pathways stimulated by rhinoviruses, the majority of the research has been focused on limiting or preventing viral infection altogether. Various approaches have been taken to halt rhinovirus infection. Prevention of virus-cell interaction has been the aim of research on viral capsid binders and cell receptor blockers. Interference with correct viral protein processing is the goal of the design and testing of protease inhibitors. Current work is attempting to interfere with viral RNA replication by testing silencing RNA molecules. In this review, we will discuss recent advances in the development and testing of human rhinovirus therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1568005043340551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lower Airway Diseases in the Paediatric Population: A Two-Year, Single-Centre, Retrospective Study.
J Clin Med
January 2025
Department of Pediatric Emergency, Regina Margherita Children's Hospital, Città della Salute e della Scienza, 10126 Turin, Italy.
: Lower airway diseases in children are one of the major causes of hospitalisation. This study aimed to evaluate the characteristics of children admitted to a tertiary pediatric hospital diagnosed with lower airway disease and to identify differences between age groups and the two years of the study. : In this single-centre retrospective observational study, demographic and clinical information about children hospitalised in the emergency pediatric ward and diagnosed with lower respiratory disease from 1 June 2021 to 30 June 2023 were retrospectively reviewed.
View Article and Find Full Text PDFEffects of and Alkylamides on Respiratory Virus Replication and IL-8 Expression In Vitro.
Molecules
January 2025
Ric Scalzo Institute for Botanical Research, Sonoran University of Health Sciences, Tempe, AZ 85282, USA.
is a perennial medicinal herb with important immunomodulatory and anti-inflammatory properties, especially purported for the alleviation of cold and flu symptoms. Different classes of secondary metabolites of the plant, such as alkylamides, caffeic acid derivatives, polysaccharides, flavonoids, and glycoproteins, are believed to be biologically and pharmacologically active. Although previous research suggests that the alkylamides present in may be responsible for reducing the symptoms associated with the common cold or flu through their immunomodulatory activity, the roles of specific alkylamides and their targets (i.
View Article and Find Full Text PDFChanges in infant respiratory pathogens pre-, during, and post-COVID-19 non-pharmacological interventions in Beijing.
Ital J Pediatr
January 2025
Department of Neonatology, Children's Hospital, Capital Institute of Pediatrics, Beijing, 100020, China.
Background: To explore the effect of non-pharmacological interventions (NPIs) on respiratory pathogen profiles among hospitalized infants aged 0-3 months in Beijing during the coronavirus disease 2019 (COVID-19) pandemic.
Methods: Respiratory specimens were collected from 1,184 infants aged 0-3 months who were hospitalized for acute respiratory infection at the Children's Hospital affiliated with the Capital Institute of Pediatrics from January 2018 to December 2023. The data were divided into three groups-the pre-epidemic (January 2018 to December 2019), epidemic prevention and control (January 2020 to December 2022), and post-epidemic (January 2023 to December 2023) groups-based on the outbreak of COVID-19 and the implementation and termination of NPIs.
Respiratory virus detections in children presenting to an Australian paediatric referral hospital pre-COVID-19 pandemic, January 2014 to December 2019.
PLoS One
January 2025
Sydney Medical School, University of Sydney, Sydney, New South Wales (NSW), Australia.
Acute respiratory infections cause significant paediatric morbidity, but for pathogens other than influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, systematic monitoring is not commonly performed. This retrospective analysis of six years of routinely collected respiratory pathogen multiplex PCR testing at a major paediatric hospital in New South Wales Australia, describes the epidemiology, year-round seasonality, and co-detection patterns of 15 viral respiratory pathogens. 32,599 respiratory samples from children aged under 16 years were analysed.
View Article and Find Full Text PDFDesigning a multi-epitope vaccine candidate against human rhinovirus C utilizing immunoinformatics approach.
Front Immunol
January 2025
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Human rhinovirus C (HRV-C) is a significant contributor to respiratory tract infections in children and is implicated in asthma exacerbations across all age groups. Despite its impact, there is currently no licensed vaccine available for HRV-C. Here, we present a novel approach to address this gap by employing immunoinformatics techniques for the design of a multi-epitope-based vaccine against HRV-C.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!